Literature DB >> 18398916

The frequency of cardiac valvular regurgitation in Parkinson's disease.

Kazuo Yamashiro1, Miki Komine-Kobayashi1, Taku Hatano1, Takao Urabe1, Hideki Mochizuki1, Nobutaka Hattori1, Yoshitaka Iwama2, Hiroyuki Daida2, Michi Sakai3, Takeo Nakayama3, Yoshikuni Mizuno4.   

Abstract

To investigate the frequency of cardiac valve regurgitation related with low dose dopamine agonists in patients with Parkinson's disease (PD), echocardiograms were analyzed in 527 consecutive PD patients (448 patients treated with dopamine agonists, 79 patients never treated with dopamine agonists as age-matched controls). The frequency of mild or above mild regurgitation of the aortic valve (AR) was significantly higher in the cabergoline group (13.7%, P < 0.05) compared with the controls (2.5%). Odds ratio adjusted by age and sex for AR was significantly higher in the cabergoline group (OR, 6.45; 95% CI, 1.46-28.60; P = 0.01): odds ratio was significantly higher in patients treated with higher daily doses (OR, 14.41; 95% CI, 3.08-67.38; P = 0.0007) and higher cumulative doses (OR, 15.29; 95% CI, 3.19-73.18; P = 0.0006). No statistical difference was identified in the frequency of the tricuspid and mitral regurgitation. None of the other dopamine agonist groups including pergolide gave higher frequency or higher odds ratio compared with the controls. None of our patients showed severe regurgitation or was operated for valvular heart disease. The question as to whether or not longer duration of low dose dopamine agonist treatment would yield the same results needs further studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398916     DOI: 10.1002/mds.22036

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

1.  The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.

Authors:  Nobuhiro Ooba; Takuhiro Yamaguchi; Kiyoshi Kubota
Journal:  Drug Saf       Date:  2011-04-01       Impact factor: 5.606

2.  Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis.

Authors:  Jacqueline H Fortier; Beatrice Pizzarotti; Richard E Shaw; Robert J Levy; Giovanni Ferrari; Juan Grau
Journal:  Heart       Date:  2019-05-25       Impact factor: 5.994

Review 3.  Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.

Authors:  R De Vecchis; C Esposito; C Ariano
Journal:  Herz       Date:  2013-06-08       Impact factor: 1.443

4.  A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.

Authors:  Cesar Luiz Boguszewski; Carlos Mauricio Correa dos Santos; Kelly Suga Sakamoto; Lilian Cassia Marini; Admar Moraes de Souza; Monalisa Azevedo
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 5.  Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review.

Authors:  Malcolm Steiger; W Jost; F Grandas; G Van Camp
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

6.  High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.

Authors:  Tomoko Oeda; Motoko Masaki; Kenji Yamamoto; Eiji Mizuta; Naoyuki Kitagawa; Tsuyoshi Isono; Satoshi Taniguchi; Kiyoshi Doi; Hitoshi Yaku; Chikao Yutani; Takashi Kawamura; Sadako Kuno; Hideyuki Sawada
Journal:  J Neural Transm (Vienna)       Date:  2008-12-10       Impact factor: 3.575

Review 7.  Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.

Authors:  Tanja Tran; James M Brophy; Samy Suissa; Christel Renoux
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749

8.  Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals.

Authors:  Florence van Hunsel; Laura Peters; Helga Gardarsdottir; Agnes Kant
Journal:  Drug Saf       Date:  2021-02-19       Impact factor: 5.606

9.  Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010.

Authors:  Sachiko Nakaoka; Tatsuro Ishizaki; Hisashi Urushihara; Toshihiko Satoh; Shunya Ikeda; Mitsutoshi Yamamoto; Takeo Nakayama
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.